DOCSLIB.ORG

Organic Chemistry Analytical Chemistry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Organic Chemistry Analytical Chemistry Derivatization Reagents 137 Amination Reagents 1 Indicators 143 Catalysts 2 Ion Pair Reagents for HPLC 147 Chiral Resolution Reagents 10 Natural Products 149 Coupling Reagents 13 Green Reagents 15 Grignard Reagents 20 Halogenation Reagents 23 Ionic Liquids 25 Life Science Lewis Acids 27 Ligands 28 Organosilicon 37 Amino Acids and Derivatives 156 Oxidizing and Reducing Agents 43 Bioactive Small-molecule Compounds 159 Protecting Reagents 47 Buffers 169 SuperDry Solvents 50 Chemical Synthesis of Carbohydrates 171 Trifluoromethylthiolating Reagents 53 Chemical Synthesis of Nucleosides 174 Wittig Reagents 55 Detergents 180 Enzyme Substrates and Inhibitors 182 Fluorescent Reagents 185 Leiker---New Cross-linker 187 Azaindoles 57 Nano-microspheres 189 Benzofurans 61 PEGylation Reagents 191 Benzothiazoles 62 Protective Agents for Freeze-Drying 193 Benzothiophenes 64 Reagents for Peptide Synthesis 194 Four-Membered Ring Compounds 66 Reagents for Proteomics Research 203 Furans 70 L-Selenomethionine 207 Imidazoles 72 Stains and Dyes 208 Indazoles 74 Indoles 76 Isoquinolines 78 Macrocyclic Compounds 80 Morpholines 83 Materials Science Oxazoles 85 Piperazines 90 Piperidines 96 Additives to Polymer Materials 211 Pyrazines 103 ATRP Reagents 216 Pyrazoles 104 Building Blocks for Organic Semiconductors 217 Pyridines 106 Monomers for Polymer Materials 226 Pyrimidines 109 Organic Linkers for MOFs 233 Pyrrolidines 114 Reagents for Photoresists Synthesis 237 Quinazolines 118 Quinolines 119 Spirocyclic Compounds 125 Sulfoximines 130 Thiazoles 131 Thiophenes 135 Key Element for Your Success Customer Support Services Product Search: Online Telephone Email Specifications, packaging Europe Europe options, pricing and stock +32 (0) 11 34 03 90 [email protected] availability information is available in our fully North and South America North and South America searchable J&K e-Shop: +1 (952) 942-3333 [email protected] China China www.jk-sci.com +86 10 8284 8833 [email protected] Quality: J&K guarantees that product quality is in compliance with the specifications listed on the J&K e-Shop or, in the case of custom orders, on the quotation provided by J&K to the customer. Bulk and Custom Synthesis: J&K offers custom synthesis for products ranging from grams to several hundred kilograms according to the customer’s quality specifications. Shipping: Most products mentioned in this J&K catalogue are available from our inventory. In-stock products are shipped within 1-3 days of order payment. All orders are shipped FOB J&K shipping point. Safety and Technical Documents: SDS, Specifications and Certificate of Analysis for each product are available online in the Technical Support section of www.jk-sci.com or by email from [email protected]. SAFETY NOTE: J&K products in this catalogue are for laboratory or industrial use only. They are not to be used for food or drug applications, or to be used on human beings or animals. Amination Reagents In the last two decades, there has been explosive progress in synthetic methods for the production of amino compounds due to the rapidly increasing number of applications in pharmaceutical and material sciences. Developing novel amination reagents for the construction of new carbon-nitrogen bonds is crucial for the synthesis of amino molecules. For this purpose, many practical amination reagents such as Di-tert-butyl- iminodicarboxylate and Diformylimide sodium salt, with their high effciency and excellent substrate diversity under mild reaction conditions, have been developed. J&K supplies various high purity amination reagents to satisfy diverse customer demands, whether for laboratory use or large scale production. Organic Chemistry References [1] Gnamm, Christian et al, Synthesis, 2008, (20), 3331-3350. [2] Yi Wang and Kuiling Ding, J. Org. Chem., 2001, 66 (9), pp 3238–3241 Cat. No. Description CAS 220009 4-Amino-4H-1,2,4-triazole, 99% 584-13-4 465497 N-Boc-p-toluenesulfonamide, 98% 18303-04-3 350996 Di-tert-butyl-iminodicarboxylate, 97% 51779-32-9 199766 N,O-Dimethylhydroxylamine hydrochloride, 99% 6638-79-5 130992 Diphenylphosphoryl azide, 98% 26386-88-9 136896 Hydroxylamine hydrochloride, 98.5% 5470-11-1 235088 Hydroxylamine sulfate, 99% 10039-54-0 276862 Hydroxylamine-O-sulfonic acid, 97% 2950-43-8 189571 O-Methylhydroxylamine hydrochloride, 99% 593-56-6 151390 Phthalimide potassium salt, 99% 1074-82-4 140876 Sodium diformylamide, 90% 18197-26-7 1 Accelerating Scientifc and Industrial Development thereby Serving Humanity Catalysts Organic Chemistry J&K offers an extensive range of metal catalysts and organocatalysts for research and manufacturing. All these products are in high demand and are praised for their high quality and competitive prices. ■ Metal Catalysts • Palladium Catalysts 982398 288223 479131 141541 Cl CH2 H2C Pd Pd CH2 Cl H2C 811200 130100 966172 181420 Ph Ph Ph Ph P Ph P Ph Cl Cl P Cl Fe Pd Fe Pd Pd Cl Cl Cl P P Ph P Ph Ph Ph CH2Cl2 Ph Ph 285586 411434 195061 242195 Cl Cl P Pd P P Pd P Cl Cl 607604 182482 963490 O Cl P Pd Pd Pd2 Cl 3 4 Cat. No. Description CAS 982398 Allylpalladium(II) chloride dimer, 98% 12012-95-2 288223 Bis(acetonitrile)dichloropalladium(II), 99% 14592-56-4 479131 Bis(acetylacetonato)palladium(II), 99% 14024-61-4 141541 Bis(dibenzylideneacetone)palladium(0), 98% 32005-36-0 811200 1,1’-Bis(diphenylphosphino)ferrocene palladium(II) chloride dichloromethane complex, 97% 95464-05-4 130100 1,1’-Bis(diphenylphosphino)ferrocene palladium dichloride, 99% 72287-26-4 966172 [1,3-Bis(diphenylphosphino)propane] palladium(II) chloride, 98% 59831-02-6 181420 Bis(tri-tert-butylphosphine)palladium, 98% 53199-31-8 285586 Bis(triphenylphosphine)palladium(II) diacetate, 98% 14588-08-0 411434 Dichlorobis(benzonitrile)palladium(II), 98% 14220-64-5 195061 Dichlorobis(tricyclohexylphosphine) palladium(II), 98% 29934-17-6 242195 Dichlorobis(triphenylphosphine) palladium(II), 98% 13965-03-2 607604 Dichloro(1,5-cyclooctadiene)palladium (II), 99% 12107-56-1 182482 Tetrakis(triphenylphosphine)palladium (0), 99.8% 14221-01-3 963490 Tris(dibenzylideneacetone)dipalladium(0), 98% 51364-51-3 2 Scientifc ey lement or our Success Catalysts • Iridium Catalysts 192969 194202 283094 807415 O H3C CH3 O H3C O Ir CH3 O O H3C CH3 O Organic Chemistry 115688 Cat. No. Description CAS 192969 Chloro(1,5-cyclooctadiene)iridium(I) dimer, 98% 12112-67-3 194202 Iridium(III) 2,4-pentanedionate, 99% 15635-87-7 283094 Pentamethylcyclopentadienyliridium(III) chloride dimer, 98% 12354-84-6 807415 Tris[1-phenylisoquinoline-C2,N]iridium (III), 99% 435293-93-9 115688 Tris(2-phenylpyridine)iridium, 99% 94928-86-6 • Nickel Catalysts 112324 102993 457030 285821 Ph Ph P Ph Ph Cl P Cl Ni Fe Ni Ni Cl P Cl P Ph Ph Ph Ph 534325 452325 420739 344201 O O- Ni2+ H C CH 3 3 2 Cat. No. Description CAS 112324 Bis(1,5-cyclooctadiene)nickel(0), 98% 1295-35-8 102993 [1,2-Bis(diphenylphosphino)ethane] dichloronickel(II), 99% 14647-23-5 457030 [1,1’-Bis(diphenylphosphino)ferrocene] dichloronickel(II), 98% 67292-34-6 285821 [1,3-Bis(diphenylphosphino)propane] dichloronickel(II), 99% 15629-92-2 534325 Dichlorobis(triphenylphosphine)nickel(II), 98% 14264-16-5 452325 Nickel(II) acetylacetonate, 96% 3264-82-2 420739 Tetrakis(triphenylphosphine)nickel(0), 95% 15133-82-1 3 344201 Tetrakis(triphenylphosphite)nickel(0), 95% 14221-00-2 Accelerating Scientifc and Industrial Development thereby Serving Humanity Catalysts Organic Chemistry • Rhodium Catalysts 113857 190993 249130 199224 + Cl H Rh - BF4 Rh Rh P Rh Cl CO 3 175583 P RhCl 3 Cat. No. Description CAS 113857 Bis(1,5-cyclooctadiene)rhodium(I) tetrafuoroborate, 98% 35138-22-8 190993 Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 12092-47-6 249130 Chlorodicarbonylrhodium(I) dimer, 98% 14523-22-9 199224 Tris(triphenylphosphine)rhodium(I) carbonyl hydride, 98% 17185-29-4 175583 Tris(triphenylphosphine)rhodium(I) chloride, 99% 14694-95-2 • Ruthenium Catalysts 283313 104033 523196 233435 Cl Cl Cl Ru Ru Ru Ru P RuCl2 Cl Cl Cl 3 102033 N N N 2+ Ru 2Cl N N 6H2O N Cat. No. Description CAS 283313 Benzeneruthenium(II) chloride dimer, 97% 37366-09-9 104033 Dichloro(1,5-cyclooctadiene) ruthenium(II), 97% 50982-12-2 523196 Dichloro(p-cymene)ruthenium(II) dimer, 98%, 33% Ru 52462-29-0 233435 Dichlorotris(triphenylphosphine)ruthenium (II), 98% 15529-49-4 102033 Tris(2,2’-bipyridyl)ruthenium(II) chloride hexahydrate, 98% 50525-27-4 4 Scientifc ey lement or our Success Catalysts • Silver Catalysts Cat. No. Description CAS 123929 Silver carbonate, 98.5% 534-16-7 166365 Silver chloride, 99% 7783-90-6 110485 Silver diethyldithiocarbamate, 98.5% 1470-61-7 544572 Silver(I) fuoride, 99% 7775-41-9 990535 Silver hexafuoroantimonate, 98% 26042-64-8 330960 Silver hexafuorophosphate, 98% 26042-63-7 375885 Silver methanesulfonate, 98% 2386-52-9 Organic Chemistry 951000 Silver nitrate, 99%, 0.1 M solution in H2O 7761-88-8 547989 Silver(I) oxide, 99% 20667-12-3 163579 Silver sulfate, 99% 10294-26-5 540056 Silver tetrafuoroborate, 99%, 55.4% Ag 14104-20-2 174441 Silver trifuoromethanesulfonate, 98% 2923-28-6 • Other Metal Catalysts 504675 969496 187053 568146 O O MoO 2+ Cl Ti Cl H C CH 2 3 3 2 502144 345185 181149 531725 CH3 CH3 Ca Cl Zr Cl O O O CH3 O CH3 Cat. No. Description CAS 504675 Aluminum acetylacetonate, 99% 13963-57-0 969496 Aluminum isopropoxide, 98% 555-31-7 187053 Bis(acetylacetonato)dioxomolybdenum (VI), 97% 17524-05-9 568146 Bis(cyclopentadienyl)titanium dichloride, 99% 1271-19-8 502144 Bis(cyclopentadienyl)zirconium dichloride, 99% 1291-32-3 345185 Calcium acetylacetonate hydrate, 98% 19372-44-2 181149 Chromium(III) acetylacetonate, 97% 21679-31-2 531725 Cobalt(III) acetylacetonate, 98% 21679-46-9 5 Accelerating Scientifc and Industrial Development thereby Serving Humanity Catalysts Organic Chemistry 379709 537056 165348 257675 H3C CH3 CH3 O O- O O O 3+ Co Cu Fe H3C CH3 O O O O O CH3 3 H3C CH3 H3C CH3 434683 162797 567109 559670 H3C CH3 CH3 H3C O O CH3 H3C CH3 O CH3 CH3 O O O Zn Zr H C H3C O O CH3 O O 3 CH3 O O H3C CH3 TiCl3 H3C CH3 Cat.
Recommended publications
  • DART-MS/MS Screening for the Determination of 1,3- Dimethylamylamine and Undeclared Stimulants in Seized Dietary Supplements from Brazil

    DART-MS/MS Screening for the Determination of 1,3- Dimethylamylamine and Undeclared Stimulants in Seized Dietary Supplements from Brazil

    Forensic Chemistry 8 (2018) 134–145 Contents lists available at ScienceDirect Forensic Chemistry journal homepage: www.elsevier.com/locate/forc DART-MS/MS screening for the determination of 1,3- dimethylamylamine and undeclared stimulants in seized dietary supplements from Brazil Maíra Kerpel dos Santos a, Emily Gleco b, J. Tyler Davidson b, Glen P. Jackson b, Renata Pereira Limberger a, ⇑ Luis E. Arroyo b, a Graduate Program of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Brazil b Department of Forensic & Investigative Science, West Virginia University, USA article info abstract Article history: 1,3-dimethylamylamine (DMAA) is an alkylamine with stimulating properties that has been used pre- Received 15 December 2017 dominantly as an additive in dietary supplements. DMAA is mostly consumed by professional athletes, Received in revised form 14 March 2018 and several doping cases reported since 2008 led to its prohibition by the World Anti-Doping Agency Accepted 18 March 2018 (WADA) in 2010. Adverse effects have indicated DMAA toxicity, and there is few data regarding its safety, Available online 22 March 2018 so it was banned by regulatory agencies from Brazil and the United States. Ambient ionization methods such as Direct Analysis in Real Time Tandem Mass Spectrometry (DART-MS/MS) are an alternative for Keywords: dietary supplements analysis, because they enable the analysis of samples at atmospheric pressure in 1,3-dimethylamylamine a very short time and with only minimal sample preparation. Therefore, the aim of this work was to DART-MS/MS Dietary supplements develop a methodology by DART-MS/MS to detect the presence of DMAA, ephedrine, synephrine, caffeine, Stimulants sibutramine, and methylphenidate in 108 dietary supplements seized by the Brazilian Federal Police Adulterants (BFP).
  • Ruthenium-Catalyzed CH Functionalization Of(Hetero)

    Ruthenium-Catalyzed CH Functionalization Of(Hetero)

    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1465 Ruthenium-catalyzed C-H Functionalization of (Hetero)arenes KARTHIK DEVARAJ ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6214 ISBN 978-91-554-9783-5 UPPSALA urn:nbn:se:uu:diva-310998 2017 Dissertation presented at Uppsala University to be publicly examined in B22, BMC, Husargatan 3, Uppsala, Uppsala, Friday, 24 February 2017 at 09:30 for the degree of Doctor of Philosophy. The examination will be conducted in English. Faculty examiner: Professor Victor A. Snieckus (Department of Chemistry, Queen's University, Canada). Abstract Devaraj, K. 2017. Ruthenium-catalyzed C-H Functionalization of (Hetero)arenes. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1465. 59 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9783-5. This thesis concerned about the Ru-catalyzed C-H functionalizations on the synthesis of 2- arylindole unit, silylation of heteroarenes and preparation of aryne precursor. In the first project, we developed the Ru-catalyzed C2-H arylation of N-(2-pyrimidyl) indoles and pyrroles with nucleophilic arylboronic acids under oxidative conditions. Wide variety of arylboronic acids afforded the desired product in excellent yield regardless of the substituents or functional group electronic nature. Electron-rich heteroarenes are well suited for this method than electron-poor heteroarenes. Halides such as bromide and iodide also survived, further derivatisation of the halide is shown by Heck alkenylation. In order to find catalytic on-cycle intermediate extensive mechanistic experiments have been carried out by preparing presumed ruthenacyclic complexes and C-H/D exchange reactions.
  • Article Download

    Article Download

    wjpls, 2020, Vol. 6, Issue 8, 61-75 Review Article ISSN 2454-2229 Mitali et al. World Journal of Pharmaceutical and Life Science World Journal of Pharmaceutical and Life Sciences WJPLS www.wjpls.org SJIF Impact Factor: 6.129 INSULIN THERAPY AND IT’S NEW APPROACHES Tejaswini S. Kawanpure and Dr. Mitali M. Bodhankar* Gurunanak College of Pharmacy, Near Dixit Nagar, Nari Road, Nagpur- 440026. Corresponding Author: Dr. Mitali M. Bodhankar Gurunanak College of Pharmacy, Near Dixit Nagar, Nari Road, Nagpur- 440026. Article Received on 01/06/2020 Article Revised on 22/06/2020 Article Accepted on 12/07/2020 ABSTRACT Diabetes mellitus is a serious pathologic condition which is responsible for major healthcare problems worldwide Insulin replacement therapy has been used in the clinical Management of diabetes mellitus for more than 84 years. Insulin has remained indispensable in dispensable in management of diabetes mellitus since its discovery in 1921. Comparatively, a large percentage of world population is affected by diabetes mellitus, out of which approximately 5-10% with type 1 diabetes while the remaining 90% with type 2. The present mode of insulin administration is by the subcutaneous route through which insulin introduced into the body in a non-physiological manner having many challenges. Hence novel approaches for insulin delivery are being explored. Challenges that have adverse effect on oral route of insulin administration mainly includes rapid enzymatic degradation in the stomach, inactivation and digestion by proteolytic enzymes in the intestinal lumen and poor permeability across intestinal epithelium because of its high molecular weight and its lipophilicity. Approaches such as liposomes, micro emulsions, nano cubicle, insulin chewing gum and so forth have been prepared to ensure the oral delivery of insulin.
  • Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry

    Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry

    molecules Article Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry Dasom Shin, Hui-Seung Kang *, Hyungsoo Kim and Guiim Moon New Hazardous Substances Division, Department of Food Safety Evaluation, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Cheongju 28159, Korea; [email protected] (D.S.); [email protected] (H.K.); [email protected] (G.M.) * Correspondence: [email protected] Received: 11 August 2020; Accepted: 17 September 2020; Published: 24 September 2020 Abstract: In this work, liquid chromatography–tandem mass spectrometry (LC-MS/MS) method was developed and validated for screening and confirmation of 64 illicit compounds in dietary supplements. The target compounds were illegally used pharmaceutical drugs, prohibited compounds, and not authorized ingredients for different therapeutics (sexual enhancement, weight loss, muscular strengthening, and relaxing products). The validation procedure was performed to evaluate selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision according to the Association of Official Analytical Chemists guidelines. The linearity was >0.98 in the range of 1 1 0.5–200 µg L− . The LOQs were in the range 1–10 µg kg− for all target compounds. The accuracy (expressed as recovery) was 78.5–114%. The precision (expressed as the relative standard deviation) was below 9.15%. The developed method was applied for the determination of illicit compounds in dietary supplements collected from websites. As a result, the total detection rate was 13.5% (27 samples detected in 200 samples). The concentrations of detected samples ranged from 0.51 1 to 226 mg g− .
  • Stimulant Medications and Supplements: Clinical Implications for the Sports Medicine Provider Collaborative Solutions for Safety in Sport

    Stimulant Medications and Supplements: Clinical Implications for the Sports Medicine Provider Collaborative Solutions for Safety in Sport

    Stimulant Medications and Supplements: Clinical Implications for the Sports Medicine Provider Collaborative Solutions for Safety in Sport Francis G. O’Connor, MD, MPH, COL, MC, USA Professor and Chair, Military and Emergency Medicine Uniformed Services University of the Health Sciences DISCLOSURE . I have no relevant financial disclosures in reference to this lecture. That being said, I am a physician in the US Army, and work for the DoD. My opinions and assertions contained herein are private views and are not to be construed as official or as reflecting the views of the U.S. Army Medical Department , Uniformed Services University or the Department of Defense at large. Case Presentation 1 . 25 y/o soldier presents to the sports medicine clinic for heat tolerance testing and a return to duty assessment; . He sustained an exertional heat stroke (EHS) during Special Forces accession. Soldier was acclimatized with no history of EHS; he had been using a pre- workout stimulant. Case Presentation 2 . 25 y/o soldier presents to the medical aid station complaining of palpitations, agitation and insomnia. He has sinus tachycardia on the monitor and reports regular use of Red Bull and caffeine gum. Unit is requesting guidance on strategies for sleep. Case Presentation 3 . A warfighter contacts the Human Performance Resource Center looking for help. Recently using a new pre- workout supplement to enhance training. Unfortunately the soldier “popped positive” on a recent urine drug screen. Case Presentation 4 . Alison is a 19 y/o transfer female basketball player. She states she has a personal history of ADHD and would like to renew her prescription for Ritalin.
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0220631 A1 Mezey Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2016/0220631 A1 Mezey Et Al

    US 2016O220631A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0220631 A1 Mezey et al. (43) Pub. Date: Aug. 4, 2016 (54) METHODS OF MODULATING Publication Classification ERYTHROPOESS WITH ARGINNE VASOPRESSIN RECEPTOR 1B MOLECULES (51) Int. Cl. A638/II (2006.01) (71) Applicant: THE USA, AS REPRESENTED BY A613 L/404 (2006.01) THE SECRETARY DEPARTMENT A613 L/46.5 (2006.01) OF HEALTH AND HUMAN A638/8 (2006.01) SERVICES, Bethesda, MD (US) A6II 45/06 (2006.01) (52) U.S. Cl. (72) Inventors: Eva M. Mezey, Rockville, MD (US); CPC ............. A61K 38/11 (2013.01); A61 K38/1816 Balazs Mayer, Budakeszi (HU); (2013.01); A61K 45/06 (2013.01); A61 K Krisztian Nemeth, Budapest (HU); 3 1/465 (2013.01); A61 K31/404 (2013.01) Miklos Krepuska, Rockville, MD (US) (73) Assignee: The USA, as represented by the (57) ABSTRACT Secretary, Departm-ent of Health and Disclosed are methods of modulating erythropoiesis with Human Service, Bethesda, MD (US) arginine vasopressin receptor 1B (AVPR1B) molecules, such Appl. No.: as AVPR1B agonists or antagonists. In one example, a (21) 15/022,531 method of stimulating erythropoiesis is disclosed including (22) PCT Fled: Oct. 1, 2014 administering an effective amount of an AVPR1B stimulatory molecule to a subject in need thereof, thereby stimulating (86) PCT NO.: PCT/US2O14/058613 erythropoiesis. Also disclosed is a method of stimulating hematopoetic stem cell (HSC) proliferation which includes S371 (c)(1), administering an effective amount of an AVPR1B stimulatory (2) Date: Mar. 16, 2016 molecule to a subject in need thereof, thereby stimulating HSC proliferation.
  • Chiral Separation for Enantiomeric Determination in the Pharmaceutical Industry

    Chiral Separation for Enantiomeric Determination in the Pharmaceutical Industry

    Chapter CHIRAL SEPARATION FOR ENANTIOMERIC DETERMINATION IN THE PHARMACEUTICAL INDUSTRY Nelu Grinberg, Su Pan Contents 6.1. INTRODUCTION ...................................................................................................................................... 235 6.2. ENANTIOMERS, DIASTEREOMERS, RACEMATES ................................................................... 236 6.3. REQUIREMENTS FOR CHIRAL SEPARATION ............................................................................ 237 6.4. THE TYPES OF MOLECULAR INTERACTIONS ........................................................................... 237 6.4.1. Chiral separation through hydrogen bonding ............................................................. 237 6.4.2. Chiral separation through inclusion compounds ....................................................... 243 6.4.2.1. Cyclodextrins ............................................................................................................ 243 6.4.2.2. Crown ethers ............................................................................................................. 245 6.4.3. Charge transfer .......................................................................................................................... 259 6.4.4. Chiral separation through a combination of charge transfer, hydrogen bonding and electrostatic interactions ........................................................................... 260 233 Chapter 6 6.4.5. Ligand exchange ......................................................................................................................
  • Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor. Christophe Leterrier, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei

    Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor. Christophe Leterrier, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei

    Constitutive endocytic cycle of the CB1 cannabinoid receptor. Christophe Leterrier, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei To cite this version: Christophe Leterrier, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei. Constitutive endocytic cycle of the CB1 cannabinoid receptor.. Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2004, 279 (34), pp.36013-36021. 10.1074/jbc.M403990200. hal-00250336 HAL Id: hal-00250336 https://hal.archives-ouvertes.fr/hal-00250336 Submitted on 6 Feb 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Supplemental Material can be found at: http://www.jbc.org/cgi/content/full/M403990200/DC1 THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 34, Issue of August 20, pp. 36013–36021, 2004 © 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A. Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor*□S Received for publication, April 9, 2004, and in revised form, June 9, 2004 Published, JBC Papers in Press, June
  • Methedrine, Neo-Synephrine, Paredrine, and Pholedrine

    Methedrine, Neo-Synephrine, Paredrine, and Pholedrine

    Br Heart J: first published as 10.1136/hrt.6.4.214 on 1 October 1944. Downloaded from CLINICAL EVALUATION OF THE PRESSOR ACTIVITY OF METHEDRINE, NEO-SYNEPHRINE, PAREDRINE, AND PHOLEDRINE BY FREDERICK PRESCOTT From the Wellcome Research Institution, London Received October 10, 1944 Recently a number of pressor drugs of the adrenaline type have come into clinical use for the treatment of low blood pressure following surgical procedures, spinal anxsthesia, circu- latory collapse, and surgical and traumatic shock. For therapeutic purposes the ideal pressor drug should be effective by the intramuscular or intravenous route; it should act rapidly; it should produce a sustained elevation of blood pressure, so that frequent injections of the drug are not necessary; and it should have no undesirable effects on the cardiovascular system and no untoward side effects. Adrenaline and ephedrine were the first drugs to be used clinically to raise the blood pressure in cases of operative shock. Their limitations, however, are nowv well known. Adrenaline may do more harm than good beca4se in thera- peutic doses intrayenously it causes a considerable rise of blood pressure, e.g. 200 mm. to 300 mm. of mercury, with a precipitous fall after a few minutes to a level lower than before. Similarly ephedrine, which for dependable results must be given intravenously, produces a http://heart.bmj.com/ sharp rise of blood pressure that lasts only for ten to twenty minutes. Other pressor drugs have been introduced with a more sustained action. In most of the studies reported on these, however, no definite criteria seem to have been employed in their evaluation, nor have the conditions of administration been standardized.
  • Appendix 1 – Protocol for Preventing Or Reversing Chronic Disease The

    Appendix 1 – Protocol for Preventing Or Reversing Chronic Disease The

    Appendix 1 – Protocol for Preventing or Reversing Chronic Disease The first author has developed a protocol over the past decade for preventing or reversing chronic disease based on the following systemic medical principle: “at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective”[1]. The protocol methodology refines the age-old principles of both reducing harm in addition to providing treatment, and allows better identification of factors that contribute to the disease process (so that they may be eliminated if possible). These contributing factors are expansive and may include a combination of Lifestyle choices (diet, exercise, smoking), iatrogenic and biotoxin exposures, environmental/occupational exposures, and psychosocial stressors. This strategy exploits the existing literature to identify patterns of biologic response using biomarkers from various modalities of diagnostic testing to capture a much broader list of potential contributing factors. Existing inflammatory bowel diseases (IBD) Biomarker Identification to Remove Contributing Factors and Implement Treatment The initial protocol steps are diagnostic. The main output of these diagnostics will be identification of the biomarker levels and symptoms that reflect abnormalities, and the directions of change required to eliminate these abnormalities. In the present study, hundreds of general and specific biomarkers and symptoms were identified from the core IBD literature. The highest frequency (based on numbers of record appearances) biomarkers and symptoms were extracted, and are listed in Table 1 (highest frequency items first, reading down each column before proceeding to the next column). They are not necessarily consensus biomarkers. They are biomarkers whose values were altered by a treatment or contributing factor, and reported in the core IBD literature.
  • Engagement of Β-Arrestin by Transactivated Insulin-Like Growth Factor Receptor Is Needed for V2 Vasopressin Receptor-Stimulated ERK1/2 Activation

    Engagement of Β-Arrestin by Transactivated Insulin-Like Growth Factor Receptor Is Needed for V2 Vasopressin Receptor-Stimulated ERK1/2 Activation

    Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation Geneviève Oligny-Longpréa, Maithé Corbanib, Joris Zhoua, Mireille Hoguea, Gilles Guillonb, and Michel Bouviera,1 aInstitut de Recherche en Immunologie et Cancérologie, Département de Biochimie and Groupe de Recherche Universitaire sur le Médicament, Universitéde Montréal, Montréal, QC, Canada H3C 3J7; and bInstitut de Génomique Fonctionnelle, Département d’Endocrinologie, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5203, Institut National de la Santé et de la Recherche Médicale Unité 661, Universités Montpellier I et II, 34094 Montpellier Cedex 05, France Edited* by Jean-Pierre Changeux, Institut Pasteur, Paris, France, and approved March 9, 2012 (received for review August 12, 2011) G protein-coupled receptors (GPCRs) have been shown to activate ceptor (EGFR) and has only been described for EGFR ligands the mitogen-activated protein kinases, ERK1/2, through both G thus far (5, 6). Although GPCR-mediated transactivation of protein-dependent and -independent mechanisms. Here, we de- several other RTKs [including the PDGF (7), FGF (8), VEGF scribe a G protein-independent mechanism that unravels an un- (9), and tropomyosin-receptor kinase A (TrkA) (10) receptors] anticipated role for β-arrestins. Stimulation of the V2 vasopressin leading to MAPK activation has been documented, the specific receptor (V2R) in cultured cells or in vivo in rat kidney medullar mechanism responsible for the RTK engagement remains poorly collecting ducts led to the activation of ERK1/2 through the metal- characterized. Intracellular scaffolding that promotes the forma- loproteinase-mediated shedding of a factor activating the insulin- tion of protein complexes with nonreceptor tyrosine kinases, such – like growth factor receptor (IGFR).
  • Ep 3311667 A1

    Ep 3311667 A1

    (19) TZZ¥¥___T (11) EP 3 311 667 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 25.04.2018 Bulletin 2018/17 A01N 43/42 (2006.01) A61K 31/44 (2006.01) (21) Application number: 17194444.0 (22) Date of filing: 08.07.2010 (84) Designated Contracting States: • SCHACHTEL, Bernard AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Jupiter, FL Florida 33477 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • TAKIGIKU, Ray PL PT RO SE SI SK SM TR Loveland, OH Ohio 45140 (US) (30) Priority: 08.07.2009 US 223999 P (74) Representative: Avidity IP 09.07.2009 US 224424 P Broers Building Hauser Forum (62) Document number(s) of the earlier application(s) in 21 JJ Thomson Avenue accordance with Art. 76 EPC: Cambridge CB3 0FA (GB) 10797879.3 / 2 451 274 Remarks: (71) Applicant: Charleston Laboratories, Inc. •This application was filed on 02-10-2017 as a Jupiter, FL 33477 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: •Claims f iled aft er the date of fil ing of the • BOSSE, Paul application/after the date of receipt of the divisional Jupiter, FL Florida 33469 (US) application (Rule 68(4) EPC) • AMELING, John Cincinnati, OH 45252-1051 (US) (54) PHARMACEUTICAL COMPOSITIONS (57) Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. EP 3 311 667 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 311 667 A1 Description CROSS-REFERENCE 5 [0001] This application claims the benefit of U.S.